Neurocrine biosciences, inc. (NBIX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash Flows from Operating Activities:
Net loss

176,512

37,012

21,090

18,065

-39,171

21,111

9,927

-51,962

-106,034

-142,542

-194,095

-219,857

-200,152

-141,090

-125,746

-123,294

-107,001

-88,929

-79,058

-60,498

-49,892

-60,542

-51,740

-46,996

-45,857

-46,090

-25,958

-17,905

-6,164

5,025

-3,134

31,326

33,803

37,571

0

0

0

Reconciliation of net income (loss) to net cash provided by (used in) operating activities:
Share-based compensation expense

82,262

75,262

67,213

60,033

53,989

58,068

58,252

55,386

53,425

42,522

37,023

33,138

30,522

28,464

26,737

34,321

31,710

28,392

24,610

13,371

11,535

10,382

9,634

8,681

7,534

6,819

6,433

6,092

5,785

5,479

5,076

4,610

3,632

2,918

0

0

0

Depreciation

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

0

0

2,697

-

2,139

1,931

1,666

1,453

1,278

1,114

1,041

1,009

963

936

893

827

759

710

674

671

691

686

680

657

623

598

606

694

0

0

0

Amortization of debt discount

19,322

18,922

18,569

18,223

17,887

17,552

17,222

16,898

15,202

10,937

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

1,389

1,389

1,373

1,358

1,300

1,326

1,311

1,296

1,174

848

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (accretion of discounts) amortization of premiums on investments

-

-

-

-

-

-1,449

-1,990

-2,224

-1,999

-1,756

-1,571

-1,676

-2,392

-3,520

-4,872

-5,893

-6,418

-6,032

-5,358

-4,777

-4,186

-3,792

-3,480

-3,079

-2,821

-2,843

-2,763

-3,003

-3,151

-3,135

-3,049

-2,678

-2,463

-2,341

0

0

0

Change in fair value of equity security investments

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of restricted equity securities

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,231

10,231

10,231

10,231

0

-730

-1,459

-2,189

-2,919

-10,175

-17,436

-25,735

-34,242

-35,495

-36,743

-36,958

-37,027

0

0

0

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-397

-344

-294

-249

-205

-53

-16

20

55

-19

14

46

78

110

142

182

222

263

305

340

378

415

434

0

0

0

Gain on sales of assets, net

-

-

-

-

-

-

-

-

-

-

-

3,467

3,454

3,431

3,406

3,390

3,351

3,334

3,308

3,286

3,267

3,222

3,198

3,179

3,169

3,170

3,155

3,127

3,086

3,074

3,103

3,166

3,162

3,195

0

0

0

Cease-use expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-584

-669

-669

-669

-85

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

82

0

0

0

Other

1,354

754

865

127

-380

-409

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in operating assets and liabilities:
Accounts receivable

75,569

69,169

59,589

52,711

27,316

25,113

24,745

36,572

43,845

31,127

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

8,524

6,424

-449

1,407

5,015

3,524

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

54,355

53,955

20,990

27,689

15,493

24,223

31,808

30,984

26,395

27,338

14,627

3,841

-182

4,398

6,762

9,352

8,040

9,841

5,504

5,142

4,279

3,698

1,228

-1,248

-1,108

-949

-567

1,176

474

-557

1,218

111

1,169

149

0

0

0

Other current assets and liabilities, net

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cease-use liability

-

-

-

-

-

-

-

-

-

-

-

-

-256

-

-322

-439

-607

-610

-637

-566

-429

-418

-410

-403

-498

-590

-558

-525

-393

-263

-4,533

-5,198

-6,352

-7,502

0

0

0

Accounts receivable under collaboration agreements and other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-288

-13,528

-1,750

-1,561

-1,727

12,878

-20,438

-1,160

-1,057

-2,813

0

0

0

Other liabilities

-

-

-

-

-

-

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

27

0

0

0

-

-

-

-

Net cash provided by (used in) operating activities

302,754

152,054

99,955

71,046

27,350

101,364

91,485

13,258

-55,460

-94,331

-166,531

-188,231

-154,327

-106,181

-89,759

-77,321

-49,025

-37,997

-38,103

-31,630

-55,556

-47,140

-42,710

-41,391

-41,286

-29,607

-27,637

-25,160

-22,178

-35,294

-15,365

-4,290

-3,322

-698

0

0

0

Cash Flows from Investing Activities:
Purchases of marketable securities

-

-

-

-

-

-

-

-

664,885

583,408

526,173

494,320

301,092

298,776

289,756

331,680

345,392

449,052

392,825

336,067

307,858

257,544

256,105

258,053

187,734

145,328

157,187

138,764

157,429

166,313

174,418

186,381

163,835

139,099

0

0

0

Sales and maturities of marketable securities

-

-

-

-

-

-

-

-

307,089

339,088

354,285

399,000

405,157

415,826

414,271

364,654

338,479

255,123

192,388

186,683

154,140

154,133

157,348

154,531

163,202

151,281

170,037

163,884

133,442

132,520

110,411

129,745

135,371

134,276

0

0

0

Purchases of debt securities available-for-sale

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sales and maturities of debt securities available-for-sale

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of equity securities

-

68,855

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investment in equity securities

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

12,148

14,748

17,946

26,761

26,912

24,812

21,179

11,624

7,378

6,940

4,910

2,883

4,729

4,108

4,589

4,128

2,395

1,934

1,545

1,498

1,637

1,612

1,364

1,126

741

545

396

700

626

971

969

1,196

1,134

750

0

0

0

Deposits and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

92

68

160

-40

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-1,796

0

0

0

Proceeds from sales of property and equipment

-

-

-

-

-

34

30

37

25

7

7

0

10

13

13

13

3

9

9

9

14

45

47

85

67

40

45

60

20

32

83

116

187

245

0

0

0

Net cash provided by investing activities

-218,873

-211,073

-151,171

-110,620

-144,865

-242,915

-196,053

-186,350

-365,149

-251,253

-176,699

-98,111

99,546

112,955

119,847

28,791

-9,465

-195,814

-202,321

-151,245

-155,729

-105,366

-100,182

-104,703

-25,314

5,340

12,498

24,458

-24,622

-34,761

-63,099

-55,893

-27,613

-3,532

0

0

0

Cash Flows from Financing Activities:
Issuance of common stock

28,013

27,313

21,811

14,137

15,995

29,530

33,348

30,880

28,469

13,865

8,328

6,635

3,859

2,390

3,295

2,706

3,529

276,992

277,756

277,500

276,015

138,731

137,049

139,226

140,577

5,302

5,540

2,997

1,415

83,702

83,436

83,363

83,482

286

0

0

0

Net cash provided by financing activities

28,013

27,313

21,811

14,137

15,995

29,530

33,348

30,880

531,250

516,646

511,109

509,416

3,859

2,390

3,295

2,706

3,529

276,992

277,756

277,500

276,015

138,731

137,049

139,226

140,577

5,302

5,540

2,997

1,415

83,702

83,436

83,363

83,482

286

0

0

0

Change in cash and cash equivalents and restricted cash

111,894

-31,706

-29,405

-25,437

-101,520

-112,021

-71,220

-142,212

110,641

171,062

167,879

223,074

-50,922

9,164

33,383

-45,824

-54,961

43,181

37,332

94,625

64,730

-13,775

-5,843

-6,868

73,977

-18,965

-9,599

2,295

-45,385

13,647

4,972

23,180

52,547

-3,944

0

0

0

Supplemental Disclosure:
Non-cash capital expenditures

1,153

953

571

-9

2,918

2,318

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-